| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
CB1 ( Ki = 250 nM ); TRPV1 ( EC50 ~50 nM )
N-Arachidonyldopamine targets two key receptors: cannabinoid receptor 1 (CB1) and transient receptor potential vanilloid 1 (TRPV1). It is a potent agonist at CB1 receptors with a Ki of 250 nM, showing 40-fold selectivity for CB1 over CB2 receptors (Ki = 12 µM). It is also a potent agonist at TRPV1 receptors with an EC50 of ~50 nM. The compound has no action at dopamine receptors. |
|---|---|
| ln Vitro |
N-Arachidonyldopamine is a potent endogenous CB1 receptor agonist with a Ki of 250 nM, showing 40-fold selectivity for CB1 over CB2 receptors. It is also a potent TRPV1 agonist with an EC50 of ~50 nM. The compound has no action at dopamine receptors. As an endogenous lipid signaling molecule, it plays multifaceted roles in mammalian physiology, including inflammation and neuroscience research.
|
| ln Vivo |
In vivo, N-arachidonyldopamine is an endogenous lipid signaling molecule that plays multifaceted roles in mammalian physiology. As a dual CB1/TRPV1 agonist, it is involved in pain modulation, inflammation, and other physiological processes. The compound is not used as a therapeutic agent but is studied for its roles in neuroscience and inflammation research. Specific in vivo efficacy studies for therapeutic applications are not documented.
|
| Enzyme Assay |
The in vitro receptor binding assay for N-arachidonyldopamine typically involves measuring its affinity for CB1 and TRPV1 receptors. For CB1 binding, membrane preparations from rat brain are incubated with varying concentrations of N-arachidonyldopamine (typically 0.001-100 µM) and a radiolabeled ligand such as [3H]CP-55940. The binding affinity (Ki = 250 nM for CB1) is determined by competition binding analysis. For TRPV1 activity, calcium flux assays are performed using TRPV1-expressing cells.
|
| Cell Assay |
In vitro cellular assays for N-arachidonyldopamine typically involve treating cells expressing CB1 or TRPV1 receptors with the compound at concentrations ranging from 0.001 to 10 µM. CB1 receptor activation is assessed by measuring cAMP production (inhibition of forskolin-stimulated cAMP). TRPV1 activation is assessed by measuring calcium influx using fluorescent calcium indicators. The compound is dissolved in DMSO and diluted in cell culture medium.
|
| Animal Protocol |
In vivo animal studies for N-arachidonyldopamine are not typically performed for therapeutic purposes, as the compound is an endogenous lipid mediator. The compound may be used in pharmacological studies to investigate the roles of CB1 and TRPV1 receptors in pain, inflammation, and other physiological processes. The compound is administered to animals via injection, and behavioral and physiological responses are measured.
|
| ADME/Pharmacokinetics |
N-Arachidonyldopamine has a molecular weight of 439.64 g/mol and formula C28H41NO3. It is an endogenous lipid mediator. The compound is soluble in organic solvents such as DMSO and ethanol. Recommended storage is at -20°C. Detailed PK parameters such as half-life, Cmax, AUC, and bioavailability would require experimental determination. The compound is also known as NADA and AA-DA.
|
| Toxicity/Toxicokinetics |
N-Arachidonyldopamine is intended for research use only and is not approved for human therapeutic applications. As an endogenous compound, it is generally considered to have low toxicity, but appropriate safety precautions should be taken when handling. Standard toxicity assessments would include acute toxicity and repeated-dose toxicity studies if required for specific applications. The compound is a dual CB1/TRPV1 agonist and may have physiological effects at high concentrations.
|
| References |
|
| Additional Infomation |
Arachidonoyl dopamine is a fatty amide, belonging to the catechol class of compounds. It is a secondary carboxylamide and also an N-(fatty acyl)-dopamine. Functionally, it is related to dopamine and arachidonic acid.
N-Arachidonyldopamine (CAS 199875-69-9) is an endogenous lipid mediator belonging to the N-acyldopamine family with a molecular weight of 439.64 g/mol and formula C28H41NO3. It is a potent CB1 receptor agonist (Ki = 250 nM, 40-fold selective over CB2) and a potent TRPV1 agonist (EC50 ~50 nM). The compound has no action at dopamine receptors. It is also known as NADA and AA-DA. The compound is not approved for clinical use. |
| Molecular Formula |
C28H41NO3
|
|---|---|
| Molecular Weight |
439.63004
|
| Exact Mass |
439.308
|
| Elemental Analysis |
C, 76.50; H, 9.40; N, 3.19; O, 10.92
|
| CAS # |
199875-69-9
|
| Related CAS # |
N-Arachidonyldopamine-d8; 1159908-42-5
|
| PubChem CID |
5282105
|
| Appearance |
Solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
640.0±55.0 °C at 760 mmHg
|
| Flash Point |
340.8±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.546
|
| LogP |
7.07
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
17
|
| Heavy Atom Count |
32
|
| Complexity |
579
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(NCCC1=CC(O)=C(O)C=C1)=O
|
| InChi Key |
MVVPIAAVGAWJNQ-DOFZRALJSA-N
|
| InChi Code |
InChI=1S/C28H41NO3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-28(32)29-23-22-25-20-21-26(30)27(31)24-25/h6-7,9-10,12-13,15-16,20-21,24,30-31H,2-5,8,11,14,17-19,22-23H2,1H3,(H,29,32)/b7-6-,10-9-,13-12-,16-15-
|
| Chemical Name |
(5Z,8Z,11Z,14Z)-N-[2-(3,4-dihydroxyphenyl)ethyl]icosa-5,8,11,14-tetraenamide
|
| Synonyms |
N-Arachidonyldopamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2746 mL | 11.3732 mL | 22.7464 mL | |
| 5 mM | 0.4549 mL | 2.2746 mL | 4.5493 mL | |
| 10 mM | 0.2275 mL | 1.1373 mL | 2.2746 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
